Evaluating Mepitel in Post-mastectomy Patients and the Role of the Skin Microbiome in Radiation Dermatitis

Launched by MAYO CLINIC · Apr 26, 2018

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years.
• • Histological confirmation of breast or chest wall malignancy
• • Primary or recurrent disease eligible
• • Post-mastectomy with or without reconstruction
• • Undergoing unilateral external beam radiotherapy at the Mayo Clinic - Rochester, MN or Mayo Clinic - Eau Claire, WI
• • Ability to complete questionnaire(s) by themselves or with assistance
• • Provide informed written consent
• • Willing to consent for photography of radiation field
• • Available to return to Mayo Clinic in within 6 weeks post-treatment for assessment
• • Able to initiate thin film usage within first 3 days of the initiation of treatment
• Exclusion Criteria:
• • Documented history of adhesive or tape allergy
• • Unable to provide written consent
• • Patients with prior radiotherapy to any portion of the planned treatment site
• • Brachytherapy patients
• • Patients with active rash, pre-existing dermatitis, lupus, or scleroderma
• • Gross dermal involvement at initiation of radiotherapy
• • Recent use of systemic or topical antibiotics or antifungal medications within 14 days of swab collection
• * Recent use of any of the following within 14 days of swab collection:
• • Systemic or topical steroids
• • Use of systemic immunosuppressant drugs
• • Use of ultraviolet light therapy
• • Clinical evidence of infection that in the judgement of the principle investigator would interfere with proper assessment of the skin microbiome
• • Prior organ or bone marrow transplant
• • Current lactation
• • Undergoing bilateral radiation